Cleavage stimulation factor 2 (CSTF2) Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P33240 |
---|---|
Clone Names | 50908330 |
Gene ID | 1478 |
---|---|
Other Names | Cleavage stimulation factor subunit 2, CF-1 64 kDa subunit, Cleavage stimulation factor 64 kDa subunit, CSTF 64 kDa subunit, CstF-64, CSTF2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP1942a was selected from the N-term region of human CSTF2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CSTF2 |
---|---|
Function | One of the multiple factors required for polyadenylation and 3'-end cleavage of mammalian pre-mRNAs. This subunit is directly involved in the binding to pre-mRNAs (By similarity). |
Cellular Location | Nucleus. Note=Localized with DDX1 in cleavage bodies |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CSTF2 is one of three (including CSTF1 and CSTF3) cleavage stimulation factors which combine to form CSTF which is involved in the polyadenylation and 3'end cleavage of pre-mRNAs. CSTF2 contains a ribonucleoprotein-type RNA binding domain. CSTF2 is upregulated during activation of B cells which results in the switch of IgM heavy chain mRNA from membrane bound form to the secreted form.
References
Takagaki, Y., et al., Mol. Cell 2(6):761-771 (1998).Martincic, K., et al., Proc. Natl. Acad. Sci. U.S.A. 95(19):11095-11100 (1998).Takagaki, Y., et al., Cell 87(5):941-952 (1996).Takagaki, Y., et al., Nature 372(6505):471-474 (1994).Takagaki, Y., et al., Proc. Natl. Acad. Sci. U.S.A. 89(4):1403-1407 (1992).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.